Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

NCT04437212 | Unknown Phase 2

• 1 other identifier: Renji-KY2019-174
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal squamous cell cancer (ESCC). However, only 20% to 40% of patients can achieve pathologic complete response (pCR) after neoadjuvant CRT with favorable prognosis and about 10% of patients have disease progression after chemoradiotherapy. How to improve the the efficacy of neoadjuvant therapy is an important clinical problem to be solved. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC especially in ESCC. In Keynote181 study, for patients with metastatic esophageal squamous cell carcinoma, regardless of PD-L1 expression, pembrolizumab significantly improved overall survival compared with chemotherapy. However, the efficacy and safety of immunotherapy therapy in surgery-based multidisciplinary treatment of local advanced esophageal cancer still need a lot of clinical studies to further confirm. The aim of this study was to evaluate the efficacy and safety of the neoadjuvant chemoradiotherapy combined with perioperative toripalimab in patients with locally advanced esophageal squamous cell cancer.

Conditions

Advanced Esophageal Squamous Cell Cancer

Outcome Measures

Primary Outcomes (1)

• Major Pathological Response Rate (MPR)

  No more than 10% of tumor cells were found in neoadjuvant surgical specimens.

  From date of surgery to 14 days later

Secondary Outcomes (4)

• 2-year disease-free survival

  From date of surgery until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.

• 2-year overall survival

  From date of randomization until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 24 months

• Incidence of Treatment-related Adverse Events as Assessed by CTCAE v5.0

  60 days after the end protocol treatment

• Perioperative complication rate

  From date of surgery to 30 days later

Study Arms (1)

Toripalimab Group

EXPERIMENTAL

All patients will receive radiation therapy scheme: 41.4Gy in 23 fractions over 5 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 45mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22,29 and 2 cycles of toripalimab 240 mg every 3 weeks after chemoradiotherapy. Esophagectomy is performed 6-8 weeks after CRT completion and after operation patients received 4 cycles of toripalimab 240 mg every 3 weeks for adjuvant treatment.

Drug: Toripalimab

Interventions

Toripalimab DRUG

Patients received toripalimab 240mg every 3 weeks 1-7 days after neoadjuvant chemoradiotherapy for 2 cycles before operation and 28-42 days after operation for 4 cycles.

Also known as: JS-001

Toripalimab Group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18 to 75 years old of either gender
• Patients with histopathological confirmed resectable thoracic esophageal squamous cell carcinoma who are anti-tumor treatment-naive;
• Clinical stage of T1-4aN1-2M0 or T3-4aN0M0 according to the 8th edition of the UICC staging system;
• ECOG PS score of 0-1;
• The indexes of hematology, biochemistry and organ function meet the following requirements: a. white blood cell count (WBC) ≥ 3.0×109/L；b. neutrophil count (ANC) ≥ 1.5×109/L; c. platelets ≥ 85×109/L; d. hemoglobin ≥ 9g/dL; e. total bilirubin ≤ 14.4µmol/L; f. ALT ≤ 75U/L; g. serum creatinine ≤ 104µmol/L and creatinine clearance rate \>60 mL/min;
• Women of childbearing age must undergo a pregnancy test within 7 days before enrolling in the treatment, and those who are negative can be enrolled. Patients of childbearing age and their sexual partners agree to use reliable methods of contraception before entering the study, during the study, and at least 180 days after the end of the study;
• Ability to understand the study and sign informed consent.

You may not qualify if:

• Patients with active infection within 2 weeks before the first use of the study drug or need to be treated with oral or intravenous antibiotics;
• A history of interstitial lung disease or non-infectious pneumonia;
• Patients whose clinician judges surgery as the first choice for the best treatment;
• A history of autoimmune diseases or abnormal immune system ;
• Patients who cannot tolerate chemoradiotherapy or surgery due to severe cardiac, lung dysfunction。
• Patients diagnosed with any other malignant tumor within 5 years before enrollment, except for malignant tumors with low risk of recurrence and risk of death, such as fully treated basal cell or squamous cell skin and carcinoma in situ of the cervix;
• Known or suspected allergy or hypersensitivity to monoclonal antibodies, any ingredients of Toripalimab, and the chemotherapeutic drugs paclitaxel or cisplatin;
• A history of immunodeficiency，including a positive HIV test result or other acquired or congenital immunodeficiency diseases, a history of organ transplantation or allogeneic bone marrow transplantation;
• Women during pregnancy or lactation;
• Other situations not suitable for enrollment.

Sponsors & Collaborators

• RenJi Hospital: lead

Study Sites (1)

Renji Hospital

Shanghai, Shanghai Municipality, 200127, China

RECRUITING

Related Publications (1)

• Xu X, Sun Z, Liu Q, Zhang Y, Shen L, Zhang C, Lin H, Hu B, Rong L, Chen H, Wang X, Zhao X, Bai YR, Ye Q, Ma X. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer. J Immunother Cancer. 2024 Mar 7;12(3):e008631. doi: 10.1136/jitc-2023-008631.

  PMID: 38458635 DERIVED

MeSH Terms

Interventions

toripalimab

Study Officials

• Xiumei Ma, doctor

  RenJi Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xiumei Ma, doctor

CONTACT

86-21-68683624; sallyma@hotmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 16, 2020
• First Posted: June 18, 2020
• Study Start: July 1, 2020
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2023
• Last Updated: June 26, 2020

Record last verified: 2020-06

Locations

CN (1)